Income statement
USD
Annual
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 21M | 4M | 140M | 5M | 13M |
| Gross Profit | 21M | 4M | 125M | 4M | 13M |
| Operating Income | -16M | -37M | 73M | -86M | -61M |
| EBITDA | -16M | -19M | 71M | -60M | -33M |
| Net Income | -9M | -21M | 67M | -63M | -33M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$4.05
+6.58% today
1Y Change
-29.97%
Window
Jun 23, 2025 → Jun 15, 2026
Coverage: 246 bars · Jun 23, 2025 → Jun 15, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
SCYNEXIS, Inc. (SCYX) is a Healthcare stock with a market cap of $40.00M and listed on NASDAQ. The stock last traded around $4.05 and down 30.0% across the available one-year price window (Jun 23, 2025 → Jun 15, 2026). Baseline metrics include revenue growth of +449.9%, EPS growth of +61.4%, a dividend yield of 0.0%. What stands out right now is revenue +449.9%, EPS +61.4%, free cash flow +78.0% with operating margin -77.9% and ROIC -29.9%. Valuation is more restrained than many high-expectation growth names at price/sales 2.1. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines SCYX price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
SCYX
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
SCYX Max Drawdown
-56.67%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for SCYX and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$13.2M
+158.6% YoY
FY Net Income
-$32.9M
+47.7% YoY
Free Cash Flow
-$55.7M
+30.2% YoY
Revenue Growth
+449.9%
EPS Growth
+61.4%
Gross Margin
100.0%
Net Margin
-41.8%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 21M | 4M | 140M | 5M | 13M |
| Gross Profit | 21M | 4M | 125M | 4M | 13M |
| Operating Income | -16M | -37M | 73M | -86M | -61M |
| EBITDA | -16M | -19M | 71M | -60M | -33M |
| Net Income | -9M | -21M | 67M | -63M | -33M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 21M | 16M | 34M | 46M | 104M |
| Total Assets | 59M | 91M | 128M | 88M | 120M |
| Total Liabilities | 10M | 36M | 55M | 85M | 79M |
| Shareholder Equity | 49M | 55M | 73M | 3M | 41M |
| Total Debt | 2M | 16M | 15M | 49M | 44M |
| Net Debt | -19M | 219K | -19M | 3M | -61M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
55M
+31.7% YoY
Capital Expenditures
1M
-12922.2% YoY
Free Cash Flow
56M
+30.2% YoY
Key ratios
Gross Margin
100.0%
Operating Margin
-77.9%
Net Margin
-41.8%
ROE
-19.0%
Debt / Equity
0.04x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.